Primary fallopian tube carcinoma – the experience of a UK cancer centre and a review of the literature

2005 ◽  
Vol 25 (7) ◽  
pp. 694-702 ◽  
Author(s):  
N. L. Clayton ◽  
K. S. Jaaback ◽  
L. Hirschowitz
Keyword(s):  
Fallopian Tube ◽  
Fallopian Tube Carcinoma ◽  
Review Of The Literature ◽  
Cancer Centre ◽  
Primary Fallopian Tube Carcinoma

Primary adenocarcinoma of the fallopian tube. Review of the literature

1993 ◽  
Vol 3 (2) ◽  
pp. 65-71 ◽  
Author(s):  
M. Baekelandt ◽  
M. Kockx ◽  
F. Wesling ◽  
J. Gerris
Keyword(s):  
Fallopian Tube ◽  
Staging System ◽  
Primary Adenocarcinoma ◽  
Fallopian Tube Carcinoma ◽  
Review Of The Literature ◽  
Lymph Node Sampling ◽  
Primary Fallopian Tube Carcinoma ◽  
Aortic Lymph Node ◽  
Firm Data

An extensive review of the currently available literature on primary fallopian tube carcinoma is presented. The role of vaginal ultrasonography and the importance of an aggressive evaluation of every tubal deformity is stressed. A staging system which takes into account recent data on the biology of this malignancy is proposed. We emphasize the largely underestimated importance of early lymphatic spread of this disease, necessitating a thorough staging laparotomy with pelvic and para-aortic lymph node sampling in the apparent early stages. The need for adjuvant treatment is obvious, but until now no firm data exist as to what the optimal strategy should be. We recommend that until more representative studies are available, ovarian carcinoma protocols should be used in clinical practice.

Preoperative Sonographic Diagnosis of Primary Fallopian Tube Carcinoma

2002 ◽  
Vol 21 (10) ◽  
pp. 1171-1173 ◽  
Author(s):  
Jimmy H. F. Yuen ◽  
Grace C. Y. Wong ◽  
Christina H. L. Lam
Keyword(s):  
Fallopian Tube ◽  
Fallopian Tube Carcinoma ◽  
Sonographic Diagnosis ◽  
Primary Fallopian Tube Carcinoma

scholarly journals Primary Fallopian Tube Carcinoma Arising in the Setting of Chronic Pelvic Inflammatory Disease

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Ibrahim M. Zardawi
Keyword(s):  
Ovarian Cancer ◽  
Pelvic Inflammatory Disease ◽  
Chronic Inflammation ◽  
Fallopian Tube ◽  
Inflammatory Disease ◽  
Fallopian Tube Carcinoma ◽  
Fallopian Tube Cancer ◽  
Primary Fallopian Tube Carcinoma ◽  
Gynaecological Malignancy

Primary fallopian tube cancer (PFTC) is a rare gynaecological malignancy, clinically often mistaken for pelvic inflammatory disease or ovarian cancer. Three primary fallopian tube carcinomas, arising in a background of chronic pelvic inflammatory disease (PID), are presented. The possible association between chronic PID and PFTC is discussed and a hypothesies linking these cancers with chronic inflammation is proposed.

scholarly journals The role of cytology in preoperative assessment od primary fallopian tube carcinoma: case report

2016 ◽  
Vol 52 (3) ◽  
pp. 415-420
Author(s):  
Roberta Rubeša-Mihaljević ◽  
Damjana Verša Ostojić ◽  
Morana D inter ◽  
Snježana Štemberger-Papić ◽  
Senija Eminović ◽  
...  
Keyword(s):  
Case Report ◽  
Fallopian Tube ◽  
Preoperative Assessment ◽  
Fallopian Tube Carcinoma ◽  
Primary Fallopian Tube Carcinoma

scholarly journals Fallopian Tube Carcinoma

2019 ◽  
Vol 15 (7) ◽  
pp. 375-382 ◽  
Author(s):  
Marina Stasenko ◽  
Olga Fillipova ◽  
William P. Tew
Keyword(s):  
Fallopian Tube ◽  
Patient Survival ◽  
Gene Mutations ◽  
Adenosine Diphosphate ◽  
Parp Inhibitors ◽  
Fallopian Tube Carcinoma ◽  
Ovarian Cancers ◽  
Primary Fallopian Tube Carcinoma ◽  
Platinum Based Chemotherapy ◽  
Dose Dense

Primary fallopian tube carcinoma is a rare and difficult to cure disease. It is often grouped under the epithelial ovarian cancer umbrella, together with primary ovarian and peritoneal carcinomas. More recent evidence has suggested that epithelial ovarian cancers originate from a fallopian tube precursor. The mainstay of treatment is surgical cytoreduction and platinum-based chemotherapy. There is much debate over the best timing for surgery and the best approach to delivering the chemotherapy: traditional intravenous once every 3 weeks regimen, versus intraperitoneal, versus dose-dense intravenous regimens. Although these debates continue, novel targeted therapies, including bevacizumab and poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors, have emerged. PARP inhibitors are particularly efficacious in patients with BRCA1/2 gene mutations, and their use has been shown to prolong patient survival. This article reviews the pathologic etiology; describes the heredity, treatment challenges, and controversies; and summarizes novel therapies in primary fallopian tube carcinoma.

Sign in / Sign up

Export Citation Format

Share Document